Amgen's Q2 earnings call highlighted robust volume growth, driven by key products like Repatha, Prolia, and LUMAKRAS, despite some headwinds from foreign exchange and pricing pressures.  The acquisition of ChemoCentryx, adding TAVNEOS, is a positive short-term catalyst.  However, the company's cautious guidance, particularly concerning foreign exchange impact on Q3 and Q4, suggests potential near-term pressure on stock price.
[-1]
